Navigation Links
Abaxis Reports Financial Performance For The First Quarter Of Fiscal 2014
Date:7/25/2013

cilities or manufacturing operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis' products and services, the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy.  Readers should also refer to the section entitled "Risk Factors" in Abaxis' annual report on Form 10-K, recent quarterly reports on Form 10-Q and Abaxis' other periodic reports filed with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Financial Tables to FollowABAXIS, INC.Condensed Consolidated Statements of Income(In thousands, except per share data)(Unaudited)Three Months EndedJune 30,20132012Revenues

$
43,169

$
42,014Cost of revenues

22,277

19,165Gross profit

20,892

22,849Operating expenses:Research and development 

3,173

2,965Sales and marketing 

10,028

11,769General and administrative

3,055

3,322Total operating expenses

16,256

18,056Income from operations

4,636

4,793Interest and other income (expense), net

404

(230)Income before income tax provision

5,040

4,563Income tax provision

1,811


'/>"/>
SOURCE Abaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abaxis, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
2. Abaxis Enters Into Definitive Agreement To Deliver 300 Piccolo Xpress Instruments For A Four-Year Drug Clinical Trial
3. Abaxis To Report First Quarter Fiscal Year 2013 Financial Results Thursday, July 26, 2012
4. Abaxis Reports Financial Performance For The First Quarter Of Fiscal 2013
5. Abaxis, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
6. Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference
7. Abaxis, Inc. to Present at CL Kings 10th Annual Best Ideas Conference 2012
8. Abaxis, Inc. to Present at UBS Global Life Sciences Conference
9. Abaxis Announces the Launch of Kidney Profile Plus Panel
10. Abaxis Announces Exclusive Distribution Agreement with Abbott
11. Abaxis, Inc. to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , June 24, 2015 ... ) has announced the addition of the ... Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging ... offering. 2015 New Frontiers in ... Challenges, Emerging Technologies, Competitive Landscape is a ...
(Date:7/1/2015)... SAN FRANCISCO , July 1, 2015 /PRNewswire/ ... study startup solutions, announced today unprecedented growth in ... "There is intense pressure to speed clinical trials ... protocols, globalization, and paper-based methods have stalled these ... "The current status of clinical trials has encouraged ...
(Date:7/1/2015)... 1, 2015  Echo Therapeutics, Inc. (NASDAQ: ... non-invasive continuous glucose monitoring and associated technologies, today ... re-designed corporate website echotx.com . Echo,s new ... technology and enhances the quality and availability of ... communicates to prospective customers and stakeholders what Echo ...
Breaking Medicine Technology:2015 New Frontiers in European Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape 2goBalto Triples Sites Managed, Further Reinforcing Market Leadership Position 2Echo Therapeutics Announces New Website Launch 2Echo Therapeutics Announces New Website Launch 3
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Sir Fazle ... annual World Food Prize today. Sir Fazle has been recognised for his outstanding contribution ... , Ambassador Ken Quinn, President of the World Food Prize Foundation, announced this ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... announced that they will welcome four new members to their industry leading Scientific ...
(Date:7/1/2015)... ... July 01, 2015 , ... DIC Corporation today announced the ... natural blue food coloring. Construction of the plant, which is located on the ... began in May 2014. After commissioning, commercial production is expected to begin in ...
(Date:7/1/2015)... ... July 01, 2015 , ... OncLive® ... Hospital Corporation of America (HCA), as it further expands its Strategic Alliance Partnership ... , With this new partnership, OncLive’s editorial and marketing teams will collaborate with ...
(Date:7/1/2015)... ... ... The 28th annual Charity Horse Show hosted by the Mid-South Horse Show Association ... Pugh Bourne Park, 343 Oakfield Road. The event will again benefit Youth Town. , ... silent auction and concessions. , Horses and riders from around the country will participate ...
Breaking Medicine News(10 mins):Health News:Sir Fazle Hasan Abed Receives World Food Prize 2Health News:Sir Fazle Hasan Abed Receives World Food Prize 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3
... taken gigantic proportions not only in the animal world but human ... wanting to visit // countries with bird flu like China, Vietnam, ... moment the unanimous voice is to take the plunge as bird ... to worry., ,The infection in humans is due to close ...
... to India for the sake of low priced cosmetic ... waistline, rhinoplasty, and breast improvements are very expensive. // ... UK every year. ,Recent figures released ... that breast enlargement topped the list of cosmetic operations ...
... beset with administrative problems, experienced another upheaval. In a ... // Dr. Hart, the Director of the program for ... Dr Hart will still continue as a full-time surgeon ... ,The UC San Diego, disappointed with the manner in ...
... A domino transplant surgery was conducted through which 3-month-old Jason ... week old baby received a heart // transplant in Ohio. ... passed away, and its organs were compatible to the two ... ,The dead child’s heart and lungs were transplanted to ...
... Canada has been warned of fines by the Government if ... Copeman Healthcare intends to establish clinics in Ottawa, Toronto, and ... charging a joining fee of $1,200, and another $2,300 towards ... ,The medicare law of the state says a fine of ...
... President George W. Bush as called for complete banning on ... as asked to reduce the medical // liability system; the ... among the American people which has reduced the number of ... talk as urged the congress to approve a complete ban ...
Cached Medicine News:Health News:More People Come To India For Cosmetic Surgery 2
... The Auto Suture™ VERSAPORT™ PLUS RPF trocar ... mm long, 5 mm-11 mm, 5 mm-12 mm, ... sleeve and shield. , ,The VERSAPORT™ PLUS ... a spring-loaded shield. Upon entry into a free ...
The SURGINEEDLE™ is a veress type needle that is used to insufflate the abdomen to create pneumoperitoneum....
... The complete line of Surgical Access ...unlike ... ,The OnePort™ trocar system is actually four ... versatile, operationally flexible and clinically adaptive to ... options in disposability and bladed or dilating ...
... The complete line of Surgical Access ...unlike ... ,The OnePort™ trocar system is actually four ... versatile, operationally flexible and clinically adaptive to ... options in disposability and bladed or dilating ...
Medicine Products: